Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Verrica Pharmaceuticals (VRCA).
Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. have amended their collaboration, sharing the costs of a global Phase 3 clinical trial for a common warts treatment, with provisions for interest on deferred payments and potential offsets against future milestone payments. Additionally, Verrica has granted Torii a warrant to purchase company stock, which vests based on trial progress milestones. The modification includes terms for license negotiations if trial data is licensed to a third party and retains original termination clauses, with the amendment details to be filed in Verrica’s upcoming quarterly report.
See more insights into VRCA stock on TipRanks’ Stock Analysis page.